Expert Interview
A Second View: Discussing the potential of Syndax Pharmaceuticals' axatilimab with chronic GVHD and the results from the AGAVE-201 trial presented at ASH.
Ticker(s): SNDXInstitution: Huntsman Cancer Institute
- Assistant Professor in the Transplant and Cellular Therapy Program at Huntsman Cancer Institute
- Treats 20 patients with chronic GVHD a month
- Clinical and research expertise is in Blood and Marrow Transplantation and GVHD with particular interest in allogeneic hematopoietic cell transplantation as well as cellular therapies such as CAR-Ts for the treatment of malignant and benign hematologic diseases in adult patients
Can you discuss the current treatment landscape for cGVHD?
Added By: sara_adminWhat are your thoughts on the poster and data presented at ASH from the AGAVE-201 trial?
Added By: sara_adminOn a scale from 1 to 10 how would you rate your level of excitement for axatilimab for your patients with cGVHD?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
